Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1381 to 1395 of 1455 results for do not do recommendations

  1. Transperineal biopsy for diagnosing prostate cancer (DG54)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer

    Diagnostics guidance
    Published
    1 June 2023
    View recommendations

    Sections for DG54

  2. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

    Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA571

  3. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA380

  4. Idelalisib for treating chronic lymphocytic leukaemia (TA359)

    Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 October 2015
    View recommendations

    Sections for TA359

  5. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  6. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA429

  7. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

    Diagnostics guidance
    Published
    20 August 2014
    View recommendations

    Sections for DG13

  8. Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

    Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G)

    Diagnostics guidance
    Published
    15 November 2017
    View recommendations

    Sections for DG31

  9. Extracorporeal shockwave therapy for Achilles tendinopathy (IPG571)

    Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.

    Interventional procedures guidance
    Published
    21 December 2016
    View recommendations

    Sections for IPG571

  10. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA663

  11. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA591

  12. Midostaurin for untreated acute myeloid leukaemia (TA523)

    Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA523

  13. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  14. Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

    Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery

    Diagnostics guidance
    Published
    7 August 2013
    View recommendations

    Sections for DG8

  15. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA676